Thomas P. O'Neil Net Worth

The estimated Net Worth of Thomas P. O'neil is at least $438 ezer dollars as of 1 September 2020. Mr neil owns over 750 units of Satsuma Pharmaceuticals stock worth over $825 and over the last 8 years he sold STSA stock worth over $0. In addition, he makes $436,960 as Chief Financial Officer at Satsuma Pharmaceuticals.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr Neil STSA stock SEC Form 4 insiders trading

Mr has made over 8 trades of the Satsuma Pharmaceuticals stock since 2017, according to the Form 4 filled with the SEC. Most recently he exercised 750 units of STSA stock worth $3,420 on 1 September 2020.

The largest trade he's ever made was exercising 8,000 units of Satsuma Pharmaceuticals stock on 18 December 2017 worth over $21,520. On average, Mr trades about 1,124 units every 66 days since 2016. As of 1 September 2020 he still owns at least 750 units of Satsuma Pharmaceuticals stock.

You can see the complete history of Mr neil stock trades at the bottom of the page.

Mr. Thomas P. O'Neil biography

Thomas P. O'Neil is the Chief Financial Officer at Satsuma Pharmaceuticals.

What is the salary of Mr Neil?

As the Chief Financial Officer of Satsuma Pharmaceuticals, the total compensation of Mr Neil at Satsuma Pharmaceuticals is $436,960. There are 5 executives at Satsuma Pharmaceuticals getting paid more, with John Kollins having the highest compensation of $1,368,100.

How old is Mr Neil?

Mr Neil is 56, he's been the Chief Financial Officer of Satsuma Pharmaceuticals since . There are 8 older and 6 younger executives at Satsuma Pharmaceuticals. The oldest executive at Satsuma Pharmaceuticals, Inc. is Alan C. Mendelson J.D., 71, who is the Sec..

Insiders trading at Satsuma Pharmaceuticals

Over the last 5 years, insiders at Satsuma Pharmaceuticals have traded over $2,307,500 worth of Satsuma Pharmaceuticals stock and bought 63,855,812 units worth $106,923,937 . The most active insiders traders include Group Holdings (Sbs) Adviso..., Capital Management, L.P.Ra ... és Nippon Biomedical Laborator.... On average, Satsuma Pharmaceuticals executives and independent directors trade stock every 38 days with the average trade being worth of $2,050,940. The most recent stock trade was executed by Ken Takanashi on 6 June 2023, trading 22,053,581 units of STSA stock currently worth $20,068,759.

What does Satsuma Pharmaceuticals do?

Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. Its lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in ASCEND Phase III clinical trials and can be self-administered with proprietary pre-filled, single-use, and nasal delivery device. The company was incorporated in 2016 and is headquartered in South San Francisco, California.

Complete history of Mr neil stock trades at Protagonist Therapeutics Inc és Satsuma Pharmaceuticals

Satsuma Pharmaceuticals executives and stock owners

Satsuma Pharmaceuticals executives and other stock owners filed with the SEC include:

• John Kollins,
  President, Chief Executive Officer, Director
• Tom O'Neil,
  Chief Financial Officer
• Detlef Albrecht,
  Chief Medical Officer
• John A. Kollins,
  Pres, CEO & Director
• Dr. Detlef F. Albrecht,
  Chief Medical Officer
• Thomas P. O'Neil,
  Chief Financial Officer
• Thomas King,
  Independent Director
• Michael Riebe,
  Independent Director
• Elisabeth Sandoval,
  Independent Director
• Ken Takanashi,
  Independent Director
• Rajeev Shah,
  Independent Director
• Thomas Soloway,
  Director
• Rob Janosky,
  Chief Commercial Officer
• Mic Iwashima,
  Vice President & Head of Operations
• Heath Lukatch,
  Independent Chairman of the Board
• Alan C. Mendelson J.D.,
  Sec.
• Robert M. Janosky,
  Chief Commercial Officer
• Dr. Shannon Strom Ph.D.,
  VP & Head of Regulatory Affairs
• Robert Schultz,
  VP & Head of CMC
• Mic Iwashima,
  VP & Head of Operations
• Capital Lp Commodore,
  10% owner
• Capital Management, L.P.Ra ...,
  
• Harbor Master Investors (Ca...,
  10% owner
• Group Holdings (Sbs) Adviso...,
  
• Thomas P. O'neil,
  Chief Financial Officer
• Capital Management, L.P.Ra ...,
  
• Mutya Harsch,
  Director
• Braden Michael Leonard,
  10% owner
• Nippon Biomedical Laborator...,
  10% owner